| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3482582 | Journal of Medical Colleges of PLA | 2011 | 5 Pages |
Abstract
Combination of lenalidomide with dexamethasone (LD) is of high effectiveness for treatment of multiple myeloma (MM), resulting in an improved overall survival, response rate, and time to progression in relapsed or refractory MM. Adverse events, especially venous thromboembolism, were generally well tolerated. In addition, lenalidomide plus dexamethasone is a potential therapy in maintenance of myeloma.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
